Drugs / APN401
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06172894 | Aug 2023 → Oct 2024 | neoplasm | invIOs GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03087591 | Apr 2017 → Jul 2019 | colorectal carcinoma, exocrine pancreatic carcinoma, metastatic malignant neoplasm in the brain | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02166255 | Dec 2014 → May 2016 | melanoma, pancreas disorder, renal cell carcinoma | Wake Forest University Health Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-06-30 | invIOs GmbH | Results Press release: invIOs reports promising Phase 1b results for cell therapy APN401 in advanced solid tumors invios.com ↗
APN401 shows a favorable safety profile and promising efficacy signals in patients with late-stage solid tumors. |
| 2024-12-16 | invIOs GmbH | Results Press release: invIOs to present progress across oncology pipeline during JP Morgan Week 2025 invios.com ↗
The full data set will provide further insights into the therapy’s potential by showing a 38% response rate, which strengthens the foundation for the deve |
| 2023-09-05 | invIOs GmbH | Regulatory Press release: invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding invios.com ↗
The study, which will be carried out under the EU’s new Clinical Trial Regulation, has received regulatory approval from the Austrian Agency for Health and Food Safety (AGES). |
| 2023-04-18 | invIOs GmbH | Results Press release: invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023 invios.com ↗
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver treatment in under 24 hours |
| 2022-11-09 | invIOs GmbH | Results Press release: invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022 invios.com ↗
The patient case report shows that a heavily pre-treated patient with metastatic appendix carcinoma achieved stable disease over the course of 27 weeks of treatment with invIOs’s Cbl b silenced cell therapy. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APN401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03087591 ↗ |
| Action | Inhibit | “APN401 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT03087591 ↗ |
| Modality | Small interfering RNA (siRNA) | “small interfering ribonucleic acid (siRNA)-transfected peripheral blood mononuclear cells APN401” NCT02166255 ↗ |
| Route | Intravenous | “Given IV” NCT02166255 ↗ |